T0	Participants 38 162	patients with symptomatic paroxysmal atrial fibrillation and/or flutter monitored with trans-telephonic electrocardiography:
T1	Participants 316 537	patients with paroxysmal atrial fibrillation or flutter (PAF/PAFL) experiencing 2 or more episodes of symptomatic PAF/PAFL during a 28-day observation period to determine the dose-response effect and safety of flecainide.
T2	Participants 569 595	143 patients at 30 centers
T3	Participants 688 700	123 patients
T4	Participants 1604 1627	patients with PAF/PAFL.